Pila Pharma AB (publ) (PILA) Earnings Call Transcript & Summary

Good afternoon, and welcome to this financial results presentation and Q&A with Pila Pharma. With us today, we have Gustav Gram, Head of Investor Relations; and Dorte Gram, CEO and Founder of Pila Pharma. [Operator Instructions] I will now hand over the mic to Pila Pharma to start the presentation. And when they have been through the presentation, the Q&A will start afterwards. [Operator Instructions] Pila Pharma your line is now live.

Thank you, Anders. Hello, everyone, to those of you who are watching live and to those of you who are watching the recap, my name is Gustav, I am the Head of Investor Relations at Pila Pharma and we are here today to our commence or new initiative with stock.io for the purpose of coming through to you online with this new sort of earnings call. And we hope that it will be a very fruitful relationship now I'm joined by our CEO, Dorte as well, who's was right on time but everything worked out great. So today, we will present a little bit around our year-end report, which was released this morning. Just for your information today, it's February 28, 2024, and it is 2:00 p.m. here in Copenhagen, where we are today. And we will commence, just running through the report very quickly, touching briefly upon the important things to us. And then after a short while, we will commence with the Q&A with questions that you have been asking before the session. So let's get started. I assume that everyone can see the front page of our report here. And if we start with the summary. 2023 was, of course, a quite challenging year, generally speaking, for any biotech that is listed and has not got any products on the market. The financial climate for funding has been challenging. But nevertheless, we feel confident going into 2024 that we still have a project that is worthwhile to bet on, first and foremost, for us, majority of shareholders almost, I would say -- and for you as well, of course. We do find that the environment is improving, and we most recently had a funding round in Q4, which we can comment on in a little bit. Do you have anything extra you wanted to touch upon regarding 2023 as a whole as a year?

Well, I think it was a year where we tried to stretch our resources to the best of our efforts. Many of you may know -- well, you touched upon how -- I mean, shares we have. I still have around 20% of the ownership of the company. So -- and for me, it's been always very important to be as cost-effective as possible and to not have a lot of flesh on the bones to keep costs low. So -- and I think that ability took us through last year where we didn't have as many resources as we could have used to. But we're through that now, and it seems that things are turning better, and we are now in progress towards the next clinical trial. So I would also say that we have -- we had -- we were waiting for some tox results, so 3-month studies results in animals and they were really good. But the delivery of the report was significantly delayed, which is, of course, something that can happen. But nevertheless, it was really problematic for us because we were waiting for that to get on to the next point. So instead of March, we had to wait until September for that actually, so 6 months the latest was problematic. But I'm sure we -- but then at the same time, we also published or showed for the first time some data that were actually quite remarkable. Now that we went back to them and looked into them again, I think they actually were the best study results. So if you recall, we did a 1-month study in people overweight or obese people with diabetes. We treated them for one month with either placebo or a fixed dose of our molecule, XEN-D0501, 4 milligrams daily. And that came out positive and not having a lot of safety concerns and a little bit of effect on insulin secretion and the 2 blood glucose after that when we did a glucose tolerance. Later on, we mentioned some samples we had in the freezer and did not have funds for that at the time. But we did find then that a marker for heart failure was significantly reduced during just this 4-week period with high statistical significance. And of course, it's not a real outcome trial where you can see that people are not dying from a dysfunctioning heart, but it is a well-recognized biomarker for cardiovascular -- not only safety but cardiovascular mortality. So if this comes out according to what is known about this biomarker then with longer trials with our molecule, we should be able to prevent heart failure, which is, of course, will contribute to reducing the number of people or overweight or obese these people with diabetes who die prematurely because of cardiovascular disease. And that is, of course, tagging right into our vision about providing a solution, hopefully cost-effective, easy-to-use solution treatment for all these. Diabetes is, of course, the primary indication. We've talked a lot about obesity last year. But everything that is related to being diabetic, there are so many comorbidities. And we believe that we can provide a solution where people can have a better life when they are alive and maybe hopefully, prolong their lives so they don't have to die 10 years before they have to. So I think that was actually fantastic result and right now discussing with the 2 and how we can -- should obviously -- should we look into hard failures. But that's a little bit further down the road. So maybe -- here's has a little bit more to you.

There we go. Yes. So we can just have a brief look here at the pipeline that we have currently. As you say, the diabetes project is currently about to commence another Phase IIa dose-finding study. Can you touch a little bit upon how this is going to be?

Yes. So first of all, as you can see, we've now made a real graphic representation of our pipeline. It's still the same molecule, but we are looking into different indications. Our diabetes project, which also includes an effect in obesity, hopefully, is, of course, the primary one. It's the one that I have been driving for 20 years almost. But we also have, as you may recall, this orphan project within a painful condition called erythromelalgi. And then as a new thing, we announced that in late November, we have entered a collaboration with professor in Sweden on investigation of the effect of our molecule on growth of what we call aorta -- abdominal aorta dilatation and it's kind of a ballooning of the aorta in the distinct part of the body. And that can lead to that. The wall of the aorta becomes so thin, so it actually ruptures and then you die from bleeding. And that's not a very nice condition. And the researchers in Sweden believe that by inhibiting the inflammation that goes along with this condition, then you could actually prevent the growth. So we have started that and the model work is ongoing, and we don't have any results yet to report, but it's interesting to be able to stretch into, yes, also another cardiovascular condition where we believe we can have a bit good effect. So in fact but when we raised -- we had a rights issue before Christmas, as you may know. And I did -- or Gustav and I did the majority of the work from our side in Pila and reduce the costs of raising funds. And I don't know if that is where you want to go with that. But anyways, we raised funds, but it wasn't enough for supporting clinical studies in both diabetes and erythromelalgia. So for the moment, we have put the [indiscernible] project or the open project on hold. I still hope we can mobilize funds for that for latest time point, but at the moment, we only prioritize the diabetes project. And getting back to your question, we are in process of still preparing for that. So with the more limited funds, we actually had to go back and redesign the study, focusing on what will be the most important things to know about. The first thing is, as I've said before, we need to go up in higher doses because with higher doses -- high doses will be needed get a better effect on glucose as compared to what we've seen before. That will be absolutely necessary for us to be able to progress this to latest clinical development and even, of course, attracting a partner that is -- will be interested in sponsoring the late-stage clinical development. So we need a better effect. And for that, we need to go up in dose and do that safely. So that will be the main -- first question. Then we have now a possibility to treat for 3 months, which is 3x as much as last time. And of course, in diabetes, we are aiming at developing a treatment for chronic treatment, so everyday dosing for maybe the whole life or hopefully, you can get out of diabetes. But otherwise, you have to stay on that to keep your diabetes under control. So it's very important, obviously, that we can keep a continued treatment without losing efficacy or getting too much side effects. So safety will be the first part and that can be done in not so many patients actually. And this is what we will use the money to look into. The second part, obviously, is the effect. Is there an effect on glucose regulation HbA1c is the biomarker for that. And we talked a lot about that during the autumn and effect on obesity. I know people have told me, but you never talked about obesity before, but it's actually inert in this. When I started the project or got the idea about this kind of treatment, it was always centered around an effect on obesity. And thereby, effect on comorbidities to obesity, including diabetes. And when I started the project, it was -- obesity was not an indication. So it was not relevant to think about developing an obesity treatment and -- but now it is. And I think most of you have seen how fantastic products, Novo Nordisk can yield, for instance, have developed that are highly effective on regulating but you say wait in obese and overweight people with or without diabetes. And I think that's really magic. I actually had the pleasure to be working on the compound -- that Novo sales. So I know that very well. And it also shows that people really want that. And the obesity market kind of -- I mean, Novo clearly have been promoting their products for a little 1 to 2 years, something like that. And that has, of course, also been other products for obesity management, but they're not really successful. But this summer, and we did an interview about that. We went to the American Diabetes meeting in San Diego and Eli Lilly presented some fantastic results and also Novo. And it's like now, they seem to have broken the code for obesity treatment. So this whole area and also many countries have acknowledged obesity as a disease for which you can register pharmacological compounds for treatment. So this obesity -- treatment of obesity with the future for diabetes treatment. Also, I believe if you can treat obesity, that usually comes before you develop diabetes. So in the future, I think there will be a willingness to first treat -- obesity so that people won't progress into later-stage diabetes where you get complications, for instance, heart failure. So we think that obesity is a really, really important end point right now. I personally truly believe we will have an effect, but we don't have any data yet. So we cannot promise it. But it's not so complicated or expensive to measure body weight. So we will do that, obviously, in the next study. And whilst calculating or redesigning this Phase IIa trial that we are going towards, we had the pleasure of inviting in a new statistical consultant, really smart and with lots of experience in this space. And it seems that we can -- for not so many more patients, we can actually get to not just a trend in obesity, if there is an effect, but actually statistically significance. We would need to add a few more patients than what we can afford right now. But let's see if we can't get around there. And then, of course, to get a significant effect on glucose, we need to go to this Phase IIb trial that we've talked about for a couple of years already, requiring 3 different dose levels and of 60 persons in each dose arm. So it would be a big study of 240 or 300 patients. But that's for later. So first, safety and then hopefully, obesity effect and that we hope to -- yes, well, let's see when if most likely, and we will not be able to start until after the summer because we'll bump into the summer holidays and so on both the doctors and nurses are also on holiday, depending on where we are. But we believe that we can maybe include some more clinical trial sites so we can have more recruiting sites. So I hope we can still be done with this study within the next year. But we'll have to see.

Yes. So thank you for the small update on our thoughts of what to see from us in 2024, hopefully. I just want to round off the report touching upon the figures. Some of you look into the financial figures, you will immediately see that the cash flow in 2023 was substantially less than in 2022. And this, obviously, indicates as well that it's been a year where there has been less activity for us in terms of clinical development.

Waiting for results.

Yes. And it's important to factor that in, of course, that like Dorte said that we -- as a company, I think our mantra almost is that we want to be as efficient as we can. So when we do not have anything planned or going on, we really strap in and try to spend as little as we can in order to make the money stretch for as long as possible. And I think that's especially important in these times when you have high inflation and a challenging funding environment. So personally, I would say kudos to Dorte and the rest of the team for really taking a decision to also -- to stretch the budget and not necessarily start raising more and more capital on unfavorable conditions for shareholders.

Yes. And I think that that's always a balance. And I hope to see many of shareholders at the Annual General Assembly and then we can discuss it. For sure, the next -- I mean, the next study that we're about to -- I mean, we are working on right now will still be a small study, and we can still have a low-cost company. But when we get beyond that, we will need some more profound resources. And it's also getting into some stages where we really cannot compromise on quality. And everybody knows that in this region here, Copenhagen in Southern Sweden, there's at least 1 really, really [indiscernible] company that looks for good employees. So it can be a little bit challenging to keep going on. If you really need people to be present in your company 24/7, you really need to be able to match the payments that the industry sets a standard for. But that's a little bit later down the road. I think we can still maneuver on a very flexible scale. And maybe on that note, I should also say that we turned into a fully virtual company last year, and that actually includes both you and me. So we had to -- well, I kindly asked us both. And since it was my idea, I accepted it and you had to accept it. So we went from actually being employed to be in consultants, that also to be more flexible. But of course, that works well, of course, for somebody like us because we will work for this company no matter what. But going forward, if we have some really important tasks to be done, that needs to be done, we, of course, need to either hire people or have engagements with the company with more people who can always send, yes, press release. For instance, some fees. But that said, to be transparent about that we have done from our side, but we could to maneuver through a little bit difficult waters, which have affected everybody in this space. And -- but we're through and we didn't go under. I don't think we will ever do that. But I think we did actually see some of our peers. Few companies had to close, which is, of course, must be really a hard thing to exit and -- yes. But we are looking forward now to move on and you have probably a lot of meeting. So we'll get around and you can look at our hereon page and see what Gustav has set up of different meetings here and there. And...

Yes. And we are -- I think we're ready for a round of Q&A. If you're still here, Anders.

Perfect. Thank you for that, Gustav and Dorte. Let's move directly to the questions and let's take them one by one here. So the first question that has been submitted goes, "Pila Pharma is positioned in an interesting field, but with some really big competitors that is further and already has an established market position. Are you worried that you will be late to the party looking at the years of development in front of you?"

Yes and no. I think -- now I don't know who posted this question, but I think they are probably thinking about the obesity space, which is emerging. If you think about the diabetes space, well, there are a lot of products in the diabetes space. What I think will make us unique is that we will, like Novo is demonstrating for the GLP-1, and have a lot of positive effects. That is our expectation with a good safety and maybe a better safety profile. And then it will not be injectable. It would be a really small tablet. So it's easy to use and not a lot of plastic waste and stuff like that. So I do think we will be competitive given that we can, of course, demonstrate this nice efficacy profile that I expect. In diabetes, you have to show an effect also on either obesity or cardiovascular function to get into the treatment cascade. I expect both. So I hope we'll be fine, but it's, of course, still my more -- my ambition, we don't have a hard core data. But as I said before, we do have data on this biomarker for heart failure, and that could actually prove very interesting. In obesity, I think that's another thing. Obviously, Novo and Lilly are plowing the way into that market and opening it actually for everybody. So what we do see is that from -- I mean, in rough figures, probably 5 companies were really interested in -- big pharma companies were interested in diabetes. And now we see some of these other companies that have lift diabetes, they are coming back into obesity. So the obesity market will be not saturated yet and weaken. But of course, we hope to partner with one of the big guys or girls because it's going to be really costly to get to market. And I don't see, at least, from where we are now that we can do it on our own. I mean intellectually, probably could, but not we need a lot of money. So I'm not too worried.

Perfect. And then you actually began to answer the next question that has also been submitted. So maybe we will just take the last part of that question. It goes around partnerships and the question would be, "When would it be beneficial for you to establish such a partnership?"

So what we have communicated before is that we have talked to -- Gustav and I have been working together for 7 years. So I'm looking at Gustav, and we have gone to partner meetings for several years talking to these usual suspects in diabetes, and I will broaden it from the next. What they have said to us before is, one, you need a good effect on glucose, and you need glucose plus, so an extra effect on obese cardiovascular and you need Phase IIb data. Before Phase IIb data, they will not embark on this. So that's for the diabetes. I think it's the same for obesity. As I think we may have to do a Phase IIb. So that's another SEK 100 million. So what is it? DKK 65 million or DKK 70 million to do that in another couple or 3 years. But I do also believe that this obesity space is so hard now and we see that many companies are looking for new molecules or back up to their own combination products and so on. So if we can show that there is a sign of an effect on obesity in this small study we're going to do, or if we can add on a few more patients so we can actually get a significant effect. I would say I would be surprised if there were not anybody who wanted to discuss that data set with us. If they want to get involved, that's another thing. But yes, so if we're locking it in -- after this next small study, but if it goes as we have expected, we need to do another big study. Then, of course, and I'm not sure -- but -- there have been questions to us before Christmas, the rights issue about our patent situation. We are working with a relatively old molecule that is off pattern now. And we have not yet resubmitted a pattern around the use of this molecule because we also want to make sure we can do -- get all indications in. But I think it will, of course, be of importance and maybe significant importance to have a patent portfolio in place. So we are working on our patent strategy to make sure that we know what to do, what can do, what we must do and what we we'll do first. I have to drink a little bit. We'll let [ him ] answer the next question.

And while you drink a little bit, you can get the next question here. The question is from an investor and it goes, "Can you provide us all with an updated time line for 2024 and 2025?"

Yes. So we're working our best to get -- now we -- as I said, we had to go a little bit back to the study design. So we have lost 1 month or 2 months of -- in the plans for that. But now we're going to get back to resuming the work on preparing for the clinical trial application. So I hope we can get that in within the next month or 2. And then we have to wait for the regulatory approval. Normally, that would take about 2 months. And -- but what I heard is that if we do it in Europe, which we will do also, then there's now our central application and that those time lines have -- that has actually affected apparently the time lines. I still hope for 2 months, but I heard yesterday, it might go up to 6 months to get approval. So that would, of course, be dramatic for us. But if it is 2 months, then we should be ready to start dosing patients after summer. And then each patient has to be treated for 3 months, and then there is some run in and run out period, so 5 months for each patient approximately. And it's not too many patients, but we have decided we want to invite more clinics, as I said. So I hope we can get this recruitment done during the autumn, so that we'll finish around new year next -- in a year from now. And then, of course, we have to close the database and calculate and so on. But safety, we can say something about quite fast. But obesity, it might take another month.

And then the next question here, there are quite some information to go over, but I will just take the questions. "What are the main side effects of your treatment? What have you seen in your clinical trials? And would you say that side effects could actually constitute beneficial effects?"

Okay. So it's a big issue, and I'll try to answer it shortly. So our molecule has a different mechanism of action than the treatments we see now. I guess most people are familiar with Novo Nordisk. For instance, products, these GLP-1 analogs, where you see that people have nausea and they throw up and they have diarrhea. That's the main thing there. And that actually can get people to discontinue the treatment because it's so unpleasant. Our side effect profile is completely different. We don't have anything on the GI tract, gastrointestinal tract. But our receptor that we work on is sitting on sensory nerves. So nerves that sense sickness from the periphery and sends [ it up ] to the brain. And that means -- and it's also pain feeling. So we can get some kind of numbness in the facial areas, actually most. And that goes away in the previous study after 2 hours or something like that. And then -- sorry, I have to train my voice again. Then also, they can -- they actually get a little bit of feeling of being warm and then that goes away. And then they feel cold again. But I think that is absolutely within our dose that's been mild and transient. So I don't expect it to be problematic. For some compounds of this drug class that have been discontinued, some patients have experienced fever and that is, of course, not good. But a little bit of increased temperature could actually be a little bit like exercise. So if you jump on a bike and do exercise for 10 minutes, you would actually get 0.5 degree increase. So if we can stay in that window and keep that, then it could contribute to energy expenditure and also body weight loss. So I hope the side effects are within the safe window and might even contribute to a desired effect of body weight loss.

Perfect. And the next ...

Without speaking.

Yes. First, engagement with stock and they're killing you already.

I had a long board meeting yesterday so maybe, yes.

The next question here. "How do you see the curve changing for the Pila Pharma to once again point and rise upwards? What would be the drivers for an upward trajectory? Would it be to perform well on weight/CDD?"

Obviously, if -- I mean -- I think actually, yesterday, there was another company that could show that they had an effect on body weight. And there is stocking up 80x, I think, or something like that. So obviously, infected will be massive, positively affecting our share. I think there are 2 components in -- not that I'm -- I mean, I'm a veterinarian by training, and I'm not very interested in stocks. But I think that it has been a big, big effect from the market on ours here that we cannot control its general market conditions. But what we can do maybe to things that can positively influence it is, of course, that we get good people on board and that we exclude according to plans. And then, of course, results are the main driver. I would say...

As you usually say, data is everything. And so I think it's very obvious if you look at companies that work in obesity and diabetes and cardiovascular disease that if they present positive data, their share goes up, and it will continue to go up. Whether they have products in the market or whether they are still in the development base like us, if they can present positive data on weight and perhaps positive data on cardiovascular disease or liver disease. We saw a Danish pharmaceutical company rise significantly on a data set presented by their partner for MASH, for the liver. So as Dorte has mentioned, there's so many components related to this metabolic syndrome around obesity. And it's adamant that if you can come up with positive data for this, there will be -- there will very likely be interest from other pharma companies, which, of course, is in investors' interests.

Yes. And I think -- I mean, obviously, I think there is room for more value if -- I can't -- I'm not allowed to say so much value but I'm sitting on my [indiscernible]. So if we get to further down the road, and I think it's also -- I had a lot of discussions with the investors about that in the beginning. And the inventor of an idea thinks that it has super big value. And the investor, of course, don't think it has value on unless they see the data. So it's kind of -- it's not a straight curve. It's kind of -- it goes very, very flat. And then if you get data then it goes up, you can see. But -- so I think that's also a little bit -- even though we've been around for some time now, we're still in the early stage in compared to companies that have more projects that are in the market and so on. It's still a little bit binary, maybe not totally binary, but it can still -- if we get effect, then that will be really good. I expect it also, of course, depends on what happens in the world with wars and stuff. But it should, on the normal surface, that continues to be very positive. And I think what is maybe a little bit lower risk in this project because we already know that there was an effect on glucose even though it was not small enough, it wasn't big enough. But we actually do know that it is an effect already of the molecule and lack of efficacy is actually what kills most project in Phase IIb. So we have already reduced the risk of failure and maybe not 100%, maybe less, of course. But -- so I think it's -- there's a higher likelihood blend for other Phase II trial stage projects that we will actually get efficacy. And we also have this huge effect on the cardiovascular effect...

So I think as well, there's something rather important to say in regards to the fact that there's really not a lot of companies operating with the same type of molecule as well we use. So everyone is flocking around the GLP-1 agonist right now. So if we could prove that our molecule works, we would be in a quite unique position where not a lot of companies would have these type of molecules very far in development. So that would give a -- not sure [indiscernible] .

So we heard that some of them actually have read up on the literature and they agree with me on the mechanism. So that is, of course, something that -- but first move is, if you come with a new idea and a new field, then it takes off -- if you could get 1 or 2 competitors to join you, that would actually not be a bad thing because it would consolidate your idea. But let's see -- but we have, at least, a very unique molecule in this drug class because other modules that blocks this receptor have been found to be associated with too much side effects, and we don't see that for our molecule. So that's so far, so good. It seems to be intolerable.

And that maybe brings us to the final question here. We have been around the partnerships, but the next question is around acquisition. "We've seen a lot of acquisition in the diabetes and obesity segment lately, mostly from companies acquiring GLP-1 antagonists looking to join the party, but also some of the established players buying early-stage projects with very different mechanisms of action, presumably to combine with the GLP-1s. Do you think something similar could happen to Pila? And when would you be a target for acquisition?"

I Think we are on the target list, at least for some companies already. And I spoke to some last year. I mean we're still too early, and we still need to demonstrate the data before we actually want to go further. But as I said, some of them acknowledge the mechanism. Some have said that yes, we need to demonstrate a little bit more data. And they also said, if it's a Phase II, it goes directly into their clinical development group, and they actually don't want us to be involved. I think -- I heard subtitles that were not very pref. So I think we are open to everything we can't claim in any partnership or acquisition or anything. The only thing we can plan is what we do going forward. And that is, of course, with a good relationship we have with our current investors and hopefully, to the more future investors to mobilize. Considering mobilizing the funds and us to using it with prudence and being cost effective, then we can move forward. So we plan to develop this project as long as it takes. And we have already -- that's actually a few years back that we went into China in '19, and you thought you actually did a case #1 after that. But -- and at that time point, we spoke to a number of Chinese companies because they are interested in joint venture projects for taking it to market, for instance, in China, and it's the same with some of the Asian countries in -- for instance Korea, Japan and so on. So we have been looking at how to get to market. I mean, we look at alternative ways to get -- I mean my biggest goal and [indiscernible] now see the global Pila. That is -- our logo is -- we are target-oriented P/A company. We want to get this drug to market because if it's safe enough and efficacious enough, it will really be a benefit for many, many people. And we might be able to tackle this problem where a lot of people are not able to treat their different conditions in metabolic syndrome. So I definitely need to get this drug to market one way or the other. But of course, for our investors, if there was a big pharma company that wanted to pay some upfront and maybe the likelihood of getting to market would be higher, then, of course, that would be fantastic. But it also needs to be the right partner, we -- they shouldn't put us on the shelf, for instance.

Yes. And that was actually all the questions that we are meant to get today. So that finalizes the Q&A. And before we end the webcast, I will just hand over the word for you, if you have any kind of final remarks to end with.

Invest?

Yes. I was actually looking into...

We will work to go upwards.

I actually looked into my -- no net account today to see what money I had available, but I need to transfer and I'm not sure. My family says I have enough shares. But anyway, I think I was thinking maybe today when I'm not inside bound anymore, I have been for even during the rights issue, I was inside a lot. I couldn't purchase shares. So yes. I think it's...

Yes. And just to conclude that it's, of course, a very interesting segment still, and it's only increasing a lot in public awareness even as well with some of these new trucks coming through that have a name recognition unlike, I think, anything that's been seen on a global basis before.

Yes. [indiscernible] they regularly write about where do we...

Yes. Yes. So they -- yes, it's commonplace now for medicine in this space to be known by everyone, not just people in the industry. So of course, that makes it very interesting and we need to follow through and show what we can do in order to drive shareholder value. And as Dorte says, to provide the world with our great invention. I think that's ultimately the goal.

That's definitely my goal. And we are looking at how to get there if we have to do it on our own. And that also, of course, includes being financially flexible during difficult times, but also we're now preparing for this scale up that we hope will get to within not so long anymore so.

Perfect. And thank you for that. Thank you, everyone, for listening in here to this webcast. Thank you for submitted questions for Pila Pharma. And thank you to Gustav and Dorte for presenting and answering questions. That ends the Q&A and the webcast, but we will be back at a later point with another presentation. So thank you, everyone, for listening in today.

Thank you.

Thank you. Thank you very much.

Take care.